UCSF Profiles

search, discover, network

Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London. He has held academic posts at the University of California, San Francisco (where he remains an Adjunct Professor) and the University of Geneva. In 2004, he joined the University of Bath as Professor of Pharmaceutical Sciences, and he currently serves as the Chair of the Research Committee of the Department of Pharmacy & Pharmacology. Dr. Guy is an elected fellow of the Academy of Pharmaceutical Scientists, Great Britain, the Royal Society of Chemistry, the Controlled Release Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science.

Dr. Guy's research focuses on skin barrier function characterization, transdermal drug delivery, enhancement of percutaneous absorption, iontophoresis, noninvasive biosensing, and the prediction and assessment of skin penetration and topical bioavailability. Dr. Guy has published 300+ peer-reviewed articles and over 70 book chapters. He has co-authored one book and co-edited 7 others. He is also co-inventor of 12 patents. Specific ongoing projects include: measurement of the skin's biomechanical properties at the nanoscale using atomic force microscopy; the detection and quantification of skin barrier disruption by surfactants found in commonly used cosmetic, personal care and pharmaceutical products; the potential of polymeric film-forming systems as sustained release platforms for topical drugs; determination of the disposition of drug and formulation excipients (including nanoparticles) post-application to the skin using coherent Raman scattering and confocal microscopy; identification of skin-penetrating constituents of traditional, topical Thai medicines and their re-formulation; development of an integrated iontophoretic delivery system for buprenorphine and naltrexone to treat polydrug abuse; examination of a graphene-based biosensor for noninvasive, transdermal glucose monitoring; and derivation and evaluation of predictive models of percutaneous penetration for pharmaceutical and cosmetic 'actives', and for potentially toxic chemicals, which come into contact with skin.